Gensler is using a new software program to help optimize social distancing in the workplace for Houston companies returning to the office. Photo courtesy of Gensler

The COVID-19 pandemic has displaced many Houstonians from their office jobs to makeshift work-from-home setups. With coronavirus cases climbing in Houston, the obstacle of returning to work safely is undoubtedly on the minds of business owners across the city.

Thankfully, there's an algorithm for that. Gensler, a global architecture firm, has unveiled its ReRun program as a pandemic response tool to help offices create workspace layouts for safe social distancing.

ReRun allows Gensler to upload a floorplan into the program, which applies generative algorithms to determine safe separation between workplaces by creating circles ranging from six to eight-foot diameters. The tool can quickly generate scenarios and identify the most optimized capacity to meet social distancing demands, easing the role of operations and human resources.

"It's really just a tip of the spear in terms of occupancy planning, because once you know that information, then the next question is what do I do with that?" says Dean Strombom, strategy lead and principal at Gensler's Houston office.

"ReRun is the first tool we utilize to help [clients] determine how many people might be able to come back and still achieve the social distancing side. Then we work with them on how they should come back, whether it's a percentage of employees, staggered shift work or alternating days," Strombom says. Circulation patterns are also taken into account by the Gensler team, who analyze the traffic of hallways, meeting spaces and lounge areas.

Dean Strombom is the strategy lead and principal at Gensler's Houston office. Photo courtesy of Gensler

The international firm, with 50 offices around the world, has rolled out the ReRun tool to its database of clientele. The platform is also available to businesses outside of the firm's existing portfolio, who can use the tool by providing a simple CAD design of their workplace. ReRun is applied through the company's SaaS space management software, Wisp. Using occupancy planning, Wisp provides clients with color-coded floor plans to help visualize and communicate to their teams which seats are available or assigned for occupancy as employees phase back into the office.

The response has been positive among clientele. Strombom is currently applying Gensler's social distancing tool with a large financial services company with locations throughout the Houston area.

"We are loading the information from ReRun into the Wisp program, and then we'll be helping them determine how they will return to work, and specifically where people will sit," he shares. The company plans to come back with 20 percent of the workforce, increasing overtime with the help of Gensler's team. "Who comes back when and specifically where is what they're most excited about."

The company has determined four work modes employees exhibit: focus, collaboration, socialization, and learning. By categorizing the work modes, Gensler is looking ahead at how interior architecture can accommodate these phases.

"More recently, we've been talking about a need for regenerative spaces so that people can become more engaged in the workplace," says Strombom.

As described in a Gensler blog, isolation rooms were optioned as a way to contain an employee who begins to feel symptomatic but these rooms can also serve a different purpose for employees acclimating to a new normal.

"The isolation room is what we often call a wellness room in an office where people can get away from the general tensions that they may be feeling in a workplace where they can relax and reinvigorate themselves in a quiet space," says Strombom.

As the architecture industry adjusts to a post-pandemic world, Gensler is working with developer clients and building owners to share the near-term and long-term changes the company foresees. Strombom says clients have flexibility as a priority.

ReRun allows Gensler to upload a floorplan into the program, which applies generative algorithms to determine safe separation between workplaces by creating circles ranging from six to eight-foot diameters. Graphic courtesy of Gensler

"We have to think about the entire path or the entire entry sequence in office buildings that is true for residential as well. From the moment that you pull into the garage, what are all of those points along the way where you've got to be concerned about contact and cleanliness?" Strombom shares.

Strombom foresees new building systems coming to the forefront, for example air conditioners with a focus on keeping clean air circulation within the office building. He also predicts a need for flexible spaces that can change depending on the circumstances.

"You hear a lot about temperature readings and separations of people within building lobbies during pandemics. We need systems in place that you can rapidly deploy when something like this happens, but the majority of the time it can revert to a more normal circumstance," he says.

Tight spaces also require a new way of thinking.

"We've realized that the elevator cab is really one of the pinch points in office buildings if you're trying to maintain this social distancing," Strombom shares. "There's technology [out there] that can identify how many people are going to be entering a cab and restrict that occupancy. So that is something that's going to need to be done for the near term."

In a Gensler survey of its Houston office, 72 percent of respondents expect a maintained or increased level of virtual collaboration compared to these pre-COVID levels.

"As people have been semi-forced to work at home, they've realized that not only is it possible, but for some people it's the preferred way to work," says Strombom, who predicts virtual meetings will continue on.

While platforms like Zoom and Skype make meetings tenable, company employees are still anticipating a future in the office.

"Those of us that are now working from home, if you ask people the majority of respondents to the question of what they miss most, it's really the people," Strombom says.

From common space to desks and offices, ReRun can help enable social distancing in the workplace. Photo courtesy of Gensler

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

4 Houston health tech startups advancing medical innovation

meet the finalists

Houston has been driving medical innovation for decades. And thanks to leading hospitals, cutting-edge research and breakthrough technologies, the region’s healthcare ecosystem continues to improve how patients are diagnosed, treated and cared for.

The Health Tech Business category in our 2025 Houston Innovation Awards will honor an innovative startup within the health and medical technology sectors.

Four forward-thinking businesses have been named finalists for the 2026 award. This year's finalists, selected by our esteemed panel of judges, range from a startup developing miniaturized medical technologies for space to a company using AI to help develop cancer treatment plans.

Read more about these businesses, their innovative founders, and how they're shaping the future of health care below.. The 2026 winners will be announced on InnovationMap.com in mid-November.

Bairitone Health

Bairitone Health is bringing anatomy imaging for sleep apnea to the home environment. The company's platform maps users' anatomy during natural sleep using a facial patch to determine the root cause of airway obstruction. It then offers effective therapies for each patient.

The company was founded in 2022 in the Texas Medical Center's Biodesign program by CEO Meagan Pitcher, CTO Onur Kilic and chief medical officer Britt Cross. It was a member of Activate Houston's inaugural cohort and has participated in numerous accelerators and incubators. The company raised an oversubscribed seed round for $2.4 million earlier this year and received Breakthrough Device Designation from the Food and Drug Administration in April.

InformAI Inc.

InformAI Inc. develops fit-to-purpose AI solutions for the clinical setting. Its RadOncAI product recently received FDA 510(k) clearance. The product uses AI to create a first-pass radiation therapy dose plan for complex head and neck cancers in an effort to eliminate bottlenecks in radiation planning and ultimately cancer treatment. The company has also developed AI products for sinus disease detection and 3D organ reconstruction.

CEO Jim Havelka founded the company in 2017. It is participating in the Mayo Clinic Accelerate Platform. It has raised about $4 million in seed funding and has received numerous non-dilutive grants from the National Science Foundation, the National Institutes of Health and the Cancer Prevention and Research Institute of Texas. The company shared in its application that it plans to launch a Series A fundraising round and submit an FDA 510K application for its organ reconstruction product, Voluquant, by the end of 2026.

Prana Surgical

Prana Surgical is developing a minimally invasive surgical platform for small, hard-to-reach lung nodules that may be cancerous. The company's Prana System cleared U.S. Food and Drug Administration (FDA) approval earlier this year.

Prana Surgical was originally founded as Prana Thoracic in 2022. It has participated in numerous accelerators, including the Texas Medical Center Innovation Accelerator in 2023 and the IGNITE Health accelerator in 2022. It raised $6 million in Series A funding rounds in 2023 and 2024 , with a Series B currently ongoing. The company said in its application that it is currently moving into the next stage of clinical validation and revenue generation in the U.S., in addition to preparing its manufacturing and commercial infrastructure for broader use.

Skybound MedTech

Skybound MedTech develops technologies that aim to address the health risks of long-duration spaceflight. Its compact, miniaturized medical technologies can deliver complex therapies without a physician.

CEO Matthew Kuhn, who previously founded Taurus Vascular, founded Skybound last year. The company emerged from stealth in January after raising a $1.25 million Series A round. It plans to advance its lead dual-use platform into critical preclinical validation in November, the company shared in its application. It is currently raising a $25 million Series A round and is pursuing federal research partnerships with DARPA and ARPA-H.

Generation Park lands new facility to scale xeno-organ production

Organ innovation

Maryland-based United Therapeutics Corp. has opened a new 77,448-square-foot facility to manufacture xeno-organs in Northeast Houston’s growing biotech hub, Generation Park.

The new Houston location is United Therapeutics’ third Designated Pathogen-Free (DPF) site, named for transplant pioneers Dr. Bartley P. Griffith and Dr. Robert A. Montgomery. The company says the new facility will enable it to scale commercial production of its xeno-organs once they receive regulatory approval.

An existing DPF facility in Virginia is supporting clinical trials for the xeno-organs, and a third site in Minnesota will also focus on commercialization with the Houston site, according to the company.

Xeno-organs are organs taken from a non-human animal source and transplanted, implanted or infused into a human recipient.

Currently, United Therapeutics is advancing clinical trials to support a Biologics License Application with the U.S. Food and Drug Administration for its investigational-stage xenotransplantation, UKidney, UThymoKidney and UHeart products. The products all involve working with the genes from humans and pigs.

In 2025, Chron.com reported the company was working to construct an estimated $96 million facility to breed genetically engineered animals. Head of investor relations at United Therapeutics Dewey Steadman told the Houston Business Journal in 2025 that the pigs’ DNA will be edited. In November 2024, a 53-year-old woman in Alabama received a transplanted kidney from UKidney that had 10 gene edits. She had the transplant removed in April 2025, after her body rejected it.

The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility requires a “strictly controlled, biosecure barrier environment, including air filtration, filtered water, filtered feed supplies, and state-of-the-art decontamination entryways,” according to the company. Being pathogen-free means it includes calibrated air and water conduits to support the transplantability of xenograft products and to prevent contamination. For energy considerations, the building also features solar arrays.

“With our third xenograft production facility now open and clinical trials underway, United Therapeutics is moving closer to its goal of providing transplantable organs to the people who need them,” Martine Rothblatt, chairperson and CEO of United Therapeutics, said in a news release. “It is fitting that this facility is named for Dr. Griffith and Dr. Montgomery, whose first-in-human surgeries turned xenotransplantation from a theoretical possibility into a clinical reality.”

The facility, which wrapped construction in August, is located at 11848 Common Dock Dr. in Generation Park, which will house manufacturing sites for pharmaceutical heavyweights Bristol Myers Squibb and Eli Lilly. Last fall, Eli Lilly tapped Generation Park for its $6.5 billion manufacturing plant, and Bristol Myers Squibb made a $2.3 billion investment in August to bring its state-of-the-art site to the master-planned commercial district.

Elon Musk's SpaceX reports profit as AI and satellite businesses booms

Booming Business

SpaceX reported a bigger quarterly profit than expected on Tuesday, October 20, as its satellite communications and artificial intelligence businesses boomed.

The company, run by Elon Musk, posted a profit for the three months through September 2026 of $4.4 billion, or 35 cents per share, reversing a year-ago loss and easily topping Wall Street's expectations. Revenue soared to $14.6 billion, up 161%.

On a conference call with analysts, Musk suggested a merger with his electric car company Tesla might be in the works, something that has been rumored for months. He said both companies formed “special committees” of independent directors to discuss the issue, though he played down the chances of an imminent deal.

“Some people out there assume that a SpaceX and Tesla merger is a certainty,” he said. “I think that would be overstating it.”

The AI business became SpaceX's largest by revenue in the third quarter, although the Starlink satellite service remains the biggest profit generator.

“They beat across all metrics and the Starlink business looks to be accelerating,” said Dan Ives, an analyst at Yorkville Ives. “This is just what (Wall) Street wanted.”

The stock rose 7.5% in after-hours trading.

Musk also told analysts that for next month's launch of its Starship rocket, SpaceX will attempt to grab both the booster and ship with mechanical arms upon return to base, a key step toward demonstrating it can reuse the massive spacecraft.

“The only way that we can extend consciousness beyond Earth on a sustained basis is with a fully reusable orbital launch vehicle,” Musk said, calling the attempt, if successful, “a massive technology milestone.”

SpaceX hopes to get Starship on a regular launch pattern in preparation for NASA's upcoming lunar missions.

The company already has huge contracts with the federal government, and House Democrats have called for investigations into those contracts and Musk’s work with the Department of Government Efficiency. Musk has spent $276 million since July in support of Republican candidates.

In a filing for its initial public offering in June, SpaceX warned that a change in control of Congress could have a “material and adverse impact on our growth and competitive position.”

Musk recently drew criticism from politicians in Washington after speeds for a military version of SpaceX's satellite communications service were slowed for Ukraine following President Donald Trump's deal to get more diesel oil from Russia amid a push to end the war. The Wall Street Journal reported Tuesday that it was Musk who ordered the slowdown, impeding Ukraine’s use of drones along the front. SpaceX did not immediately respond to an Associated Press request for comment on the Journal story.

Both Trump and Musk have denied responsibility for the slowdown.

As midterm elections near, Musk on Monday promised to give one share of SpaceX to “every kid in America” next year, though he provided no details on how the distribution would be carried out. With communities nationwide protesting the construction of large data centers and concerns about AI safety, AI companies are trying to build goodwill. Anthropic pledged to commit 5% of its shares to a new “public benefit” fund.

SpaceX shares have been under pressure over concerns that the company was spending too much on major projects to compete with rivals such as Anthropic. The company said capital expenditures totaled $19.6 billion last quarter, nearly triple the figure from a year earlier, and it forecast spending would grow to $35 billion to $40 billion in the current quarter.

Shares of SpaceX closed Tuesday at $147.79, down from a peak near $201 after its IPO, which made Musk the world’s first trillionaire at the time. But the share prices for SpaceX and Tesla have since dropped, reducing his net worth to $925 billion, according to Forbes magazine.

Tesla reports third-quarter financial results Wednesday. Last week, Tesla unveiled a new Roadster sports car that in some versions may include thrusters allowing it to briefly fly using SpaceX technology — though experts say anything usable for drivers is a long shot.